Identifying compounds for pharmaceutical companies’ development tracks using a multi-criteria decision model

Abstract

Pharmaceutical companies are faced with identifying development compounds for their Drug Development Processes (DDPs) that will not only gain approval for sale by the regulatory agencies, such as the Food and Drug Administration (FDA), but also establish a sustainable and profitable market presence. This identification of compounds for the DDP includes projection of objective criteria, such as ability to generate revenue and profitability (Financial) and safety and efficacy (Clinical), as well as more subjective criteria, such as determination of insurance coverage by payers, such as the Centers for Medicare and Medicaid Services and pricing (Reimbursement), ability to produce a product of consistent quality (Manufacturing), and attain approval for sale in a timely manner (Registration). The Analytical Hierarchy Process (AHP) is a multi-criteria decision model that can integrate both objective and subjective information. This study applies the AHP methodology to the identification of compounds resulting in a dynamic application of the model that can be used by pharmaceutical companies to determine the best compounds to put in the DDP, at a time when the cost of conducting clinical evaluations for development compounds is very high and global market conditions are evolving.

Citation

Hogan, K.M., Olson, G.T. and Sillup, G.P. (2006), "Identifying compounds for pharmaceutical companies’ development tracks using a multi-criteria decision model", Lawrence, K.D. and Klimberg, R.K. (Ed.) Applications of Management Science: In Productivity, Finance, and Operations (Applications of Management Science, Vol. 12), Emerald Group Publishing Limited, Leeds, pp. 89-108. https://doi.org/10.1016/S0276-8976(06)12008-8